irinotecan

P2, N=73, Completed, Gruppo Oncologico Italiano di Ricerca Clinica | Unknown status --> Completed | Trial completion date: Sep 2022 --> Oct 2024 | Trial primary completion date: Sep 2022 --> Aug 2024

P1/2, N=70, Not yet recruiting, STCube, Inc.

P3, N=502, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Aug 2025 --> May 2026

Paclitaxel, nab-paclitaxel, and irinotecan, either as monotherapies or in combination with ramucirumab, are currently standard second-line treatments for GC. This trial could provide valuable insights into overcoming immune resistance and contribute to developing a promising second-line therapeutic strategy for advanced GC. ClinicalTrials.Gov, identifier NCT06349967.

P2, N=126, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Not yet recruiting --> Recruiting | Initiation date: Dec 2024 --> Mar 2025

P=N/A, N=30, Not yet recruiting, French Society of Digestive Endoscopy | Initiation date: Jan 2025 --> Apr 2025

P1/2, N=27, Not yet recruiting, University of Alabama at Birmingham

P2, N=53, Terminated, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | N=112 --> 53 | Recruiting --> Terminated; Efficacy endpoint not met according to first step of Briant-Day design

P1, N=24, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

P1, N=167, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed

P1, N=1200, Recruiting, Amgen | Trial completion date: Mar 2028 --> Dec 2027

P2, N=66, Active, not recruiting, Taiho Oncology, Inc. | Recruiting --> Active, not recruiting | Trial completion date: May 2025 --> Jan 2027 | Trial primary completion date: Jan 2025 --> Jul 2025

The patient received upfront modified FOLFIRINOX (infusional 5-fluorouracil, irinotecan, and oxaliplatin) chemotherapy due to rapidly progressive symptoms, demonstrating an early and sustained treatment response. Therefore, we identified potential genetic determinants of tumorigenesis and progression in a pathologically and clinically aggressive SPN, which may have important prognostic and treatment implications.

These findings indicate that irinotecan plus trastuzumab is feasible with modest potential efficacy against chemotherapy-refractory advanced HER2-positive gastric cancer.

P2, N=85, Not yet recruiting, Yonsei University

P2, N=119, Recruiting, Fudan University

P2, N=70, Active, not recruiting, Inspirna, Inc. | Trial completion date: Dec 2026 --> Mar 2025 | Trial primary completion date: Sep 2025 --> Jan 2025

Plasma miR-379 appears clinically useful as a predictive biomarker to identify which patients with advanced PDAC benefit most from treatment with FOLFIRINOX or gemcitabine-nab-paclitaxel. Further validation in larger studies and clinical trials is now warranted.

P1/2, N=170, Recruiting, Akeso | Not yet recruiting --> Recruiting | N=72 --> 170 | Trial completion date: Jul 2025 --> Aug 2026 | Trial primary completion date: May 2024 --> May 2026

Finally, we identified six top-ranked drug molecules (NVP.BHG712, Irinotecan, Olaparib, Imatinib, RG-4733, and Linsitinib) as potential common treatments for PC, KC and T2D during their co-existence, supported by the literature reviews. Thus, this bioinformatics study provides valuable insights and resources for developing a genome-guided common treatment strategy for PC and/or KC patients who are also suffering from T2D.

The study indicates that GQD extract improves CPT-11 efficacy in treating colorectal cancer and provides insights into the synergistic effects of TCM formulas in cancer treatment.

Furthermore, hesperidin enhanced intestinal barrier function by upregulating tight junction proteins, mitigating epithelial damage, and reducing the expression of IL-17A, TARF6, p38, phosphorylated-p38 (P-p38), and AP-1 proteins in the colon. These findings suggest that hesperidin supplementation mitigates CID by modulating gut microbiota and inhibiting the IL-17 signaling pathway, thereby improving intestinal barrier integrity.

P2, N=254, Recruiting, Akeso | N=104 --> 254 | Trial completion date: Dec 2026 --> Aug 2028 | Trial primary completion date: Dec 2024 --> May 2026

P2, N=25, Not yet recruiting, EXACT Therapeutics AS

This case highlights a rare presentation of pancreatic cancer in CS/PHTS with distinct molecular and histological features. The absence of KRAS mutation and presence of germline PTEN variant may have contributed to the aggressive clinical course and treatment resistance. These findings underscore the need for further research into the molecular mechanisms of PTEN-associated pancreatic cancers and the development of targeted therapeutic strategies.

P1/2, N=51, Recruiting, Fujian Cancer Hospital | N=20 --> 51 | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Oct 2024

P1, N=22, Recruiting, Medical College of Wisconsin | Trial completion date: Jun 2026 --> Jan 2029 | Trial primary completion date: Jun 2025 --> Apr 2027

P2, N=88, Not yet recruiting, UNICANCER

P1, N=54, Suspended, EMD Serono Research & Development Institute, Inc. | Recruiting --> Suspended

P1, N=20, Recruiting, University of Louisville | Trial completion date: Jul 2024 --> Jul 2026 | Trial primary completion date: Dec 2023 --> Jul 2026

P2, N=38, Completed, Stanford University | Active, not recruiting --> Completed

P1, N=14, Active, not recruiting, Centre Hospitalier Universitaire Vaudois | Recruiting --> Active, not recruiting

P1/2, N=37, Recruiting, Shandong Cancer Hospital and Institute

P3, N=1147, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting

By exploring the specific toxicities of ADCs observed by organ, we identified that most were related to the payload mechanism of action, like the ≥G3 diarrhea observed in 10% of patients treated with sacituzumab govitecan (the payload SN-38 is the active metabolite of irinotecan), and very few were related to the presence of the TAA in normal tissue (presence of Nectin-4 in skin and ≥G3 rash toxicity in 14% of patients treated with enfortumab vedotin). In line with this, no major differences in ≥G3 toxicities were identified in studies with different levels of the TAA (trastuzumab deruxtecan in Destiny Breast Studies with different HER2 expression levels). Our analysis reveals that most ADC toxicities are driven by the payload's effects on non-transformed tissues; however, a detailed analysis of each ADC component should be taken into consideration.

Treatment of refractory and relapse/progressive HR-NB is highly heterogeneous. We confirm a poor outcome, although certain epidemiological and treatment-related factors have prognostic value. Molecular profiling and inclusion in CTs should be improved.

P2, N=116, Recruiting, Fudan University

P1/2, N=40, Recruiting, West Virginia University | Trial completion date: Jun 2028 --> Jun 2030 | Trial primary completion date: Jun 2025 --> Jun 2027

P=N/A, N=100, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

P1/2, N=21, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Sep 2025 --> Feb 2025 | Trial primary completion date: Sep 2025 --> Feb 2025

P2, N=219, Active, not recruiting, UNICANCER | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Dec 2024 --> Dec 2025

The PREOPANC-4 program aims to safely implement the international multidisciplinary best-practice for LAPC leading to benchmark outcomes for both short-term morbidity, mortality, and OS.